<DOC>
	<DOCNO>NCT02715505</DOCNO>
	<brief_summary>This study design assess safety exploratory efficacy use HSC835 patient Inherited Metabolic Disorders ( IMD ) undergo stem cell transplantation .</brief_summary>
	<brief_title>Safety Exploratory Efficacy HSC835 Patients With Inherited Metabolic Disorders ( IMD )</brief_title>
	<detailed_description>This phase II study design assess safety Novartis product HSC835 ability achieve donor blood stem cell engraftment patient certain Inherited Metabolic Disorders undergo stem cell transplantation . A reduced intensity conditioning use prior transplantation . Patients Hurler syndrome , MLD , Krabbe cALD could eligible study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>Diagnosed Hurler syndrome , Metachromatic leukodystrophy ( MLD ) , Globoid cell leukodystrophy ( Krabbe ) Cerebral adrenoleukodystropy ( cALD ) Adequate organ function Availability eligible donor material Availability matchedrelated donor carrier genetic defect Active infection screen Prior myeloablative transplant Pregnant nursing woman woman child bear potential unless use highly effective contraception method . For pediatric population , female patient child bear potential agree abstinence agree use highly effective contraception method Sexually active male patient unless use condoms contraception Human Immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hurler syndrome , MLD , Krabbe , cALD , Hematopoietic Stem Cell Transplantation ( HSCT )</keyword>
</DOC>